NCT03558750View on ClinicalTrials.gov

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

April 16, 2019

Study Completion Date

April 16, 2019

Conditions
Recurrent Central Nervous System LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Central Nervous System LymphomaRefractory Diffuse Large B-Cell Lymphoma
Interventions
BIOLOGICAL

Nivolumab

Given by IV

BIOLOGICAL

Rituximab

Given by IV

DRUG

Lenalidomide

Given by mouth

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER